Rexahn shares soar ahead of update; Nycomed says Daxas setback won't stop IPO;

 @FierceBiotech: Sanofi opens R&D center in China. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion IPO on Friday prices at $5, closes at 5.02. High risk, no revenue not what investors are looking for these days. | Follow @JohnCFierce

> Shares of Rexahn vaulted 27 percent this morning as the company announced a corporate update for tomorrow. Report

> Despite a recent setback for its drug Daxas, which earned a thumb's down vote recently from an FDA advisory panel, Nycomed says it still plans to go public. Story

> The UK's Proximagen says it will gain an upfront payment as part of a new U.S. licensing deal for its epilepsy drug tonabersat. Story

> RXi and miRagen have inked a deal to collaborate on new drugs for heart and muscle diseases. No financial terms were revealed. Story

> GenVec says it presented "encouraging" clinical and preclinical malaria vaccine data at the Keystone Symposium--Malaria: New Approaches to Understanding Host-Parasite Interactions. GenVec release

> Optimer Pharmaceuticals released top-line results from its second fidaxomicin Phase III clinical study in patients with Clostridium difficile infection at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases. Optimer release

> Federal Bankruptcy Court Judge Theodor C. Albert has confirmed Cobalis Corp's plan for reorganization. Release

And Finally... Overlooking the obvious in your surroundings? That's because your brain predicts what you will see in familiar settings. It's only when you see something unusual that your brain kicks in. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.